Last reviewed · How we verify
Dexamethasone Mouthwash
Dexamethasone is a corticosteroid that suppresses local inflammation and immune responses in the oral cavity when applied topically as a mouthwash.
Dexamethasone is a corticosteroid that suppresses local inflammation and immune responses in the oral cavity when applied topically as a mouthwash. Used for Oral inflammation and ulceration, Aphthous ulcers, Oral lichen planus.
At a glance
| Generic name | Dexamethasone Mouthwash |
|---|---|
| Sponsor | Woman's |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology / Oral Medicine |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone binds to glucocorticoid receptors in oral tissues, reducing the production of pro-inflammatory cytokines and inhibiting immune cell infiltration. This anti-inflammatory action helps reduce swelling, pain, and erythema in oral conditions. The topical formulation delivers the drug directly to affected oral tissues while minimizing systemic absorption.
Approved indications
- Oral inflammation and ulceration
- Aphthous ulcers
- Oral lichen planus
- Post-operative oral inflammation
Common side effects
- Oral candidiasis (thrush)
- Local irritation or burning
- Taste disturbance
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) (PHASE3)
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (PHASE1, PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone Mouthwash CI brief — competitive landscape report
- Dexamethasone Mouthwash updates RSS · CI watch RSS
- Woman's portfolio CI